Publication | Closed Access

Two-Year Survival Follow-Up of the Randomized, Double-Blind, Placebo-Controlled Phase II Study of Radium-223 Chloride in Patients With Castration-Resistant Prostate Cancer and Bone Metastases

UrologySurgical OncologyGenitourinary CancerMedicineTwo-year Survival Follow-upRadium-223 ChlorideCastration-resistant Prostate CancerCancer TreatmentProstatic DiseaseOncologyRadiation Oncology